A Risk-Benefit Assessment of HIV Protease Inhibitors

Author： Moyle G.J.   Gazzard B.G.  

Publisher： Adis International

ISSN： 0114-5916

Source： Drug Safety, Vol.20, Iss.4, 1999-04, pp. : 299-321

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Risk-benefit of HMG-CoA reductase inhibitors in the treatment of HIV protease inhibitor-related hyperlipidaemia

By Penzak Scott R   Chuck Susan K  

Expert Opinion on Drug Safety, Vol. 1, Iss. 1, 2002-05 ,pp. : 5-17

Informa Healthcare

Access to resources Recommend Favorite

A Risk-Benefit Assessment of Interleukin-2 as an Adjunct to Antiviral Therapy in HIV Infection

By Piscitelli S.C.  

Drug Safety, Vol. 22, Iss. 1, 2000-01 ,pp. : 19-31

Adis International

Access to resources Recommend Favorite

A Risk-Benefit Assessment of Abciximab in Angioplasty

By Kleiman N.S.  

Drug Safety, Vol. 20, Iss. 1, 1999-01 ,pp. : 43-57

Adis International

Access to resources Recommend Favorite

A Risk-Benefit Assessment of Amifostine in Cytoprotection

By Mabro M.  

Drug Safety, Vol. 21, Iss. 5, 1999-11 ,pp. : 367-387

Adis International

Access to resources Recommend Favorite

A Risk-Benefit Assessment of Antileukotrienes in Asthma

By Smith L.J.  

Drug Safety, Vol. 19, Iss. 3, 1998-09 ,pp. : 205-218

Adis International

Access to resources Recommend Favorite